Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PositronPOSC +5.51%30 Days Payable is 58.33 as of Dec. 2025, which is 73% below its 10-year median of 213.73. GuruFocus rates POSC with a GF Score™ of 30/100 and a GF Value™ of $0.12 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 794 Medical Devices & Instruments companies, Positron ranks worse than 60.2% on this metric.
Positron's average Accounts Payable for the
six
months ended in Dec. 2025 was $0.41 Mil. Positron's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $2.58 Mil.
Hence, Positron's Days Payable for the
six
months ended in Dec. 2025 was 29.16.
The historical rank and industry rank for Positron's Days Payable or its related term are showing as below:
POSC'
s Days Payable Range Over the Past 10 Years
Min: 50.27 Med: 213.73 Max: 511.94
Current: 58.33
During the past 13 years, Positron's highest Days Payable was 511.94. The lowest was 50.27. And the median was 213.73.
POSC's Days Payable is ranked worse than 60.2% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs POSC: 58.33
Positron's Days Payable
declined
from Dec. 2014 (202.20) to Dec. 2025 (58.33).
It may suggest that Positronaccelerated paying its suppliers.
The historical data trend for Positron's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Positron's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Positron Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Positron's Days Payable distribution charts can be found below:
* The bar in red indicates where Positron's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Positron's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Positron (POSC) has a Days Payable of 58.33 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Positron and its competitors. This is 73% below median its historical median of 213.73. Over the past decade, Positron's Days Payable has ranged from 50.27 to 511.94. According to the industry distribution chart, Positron ranks #478 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 60.2%.
Is Positron's Days Payable too high?
Positron's current Days Payable of 58.33 is 73% below median its 10-year median of 213.73. Over the past 10 years, this metric has ranged from a low of 50.27 to a high of 511.94. The Medical Devices & Instruments industry median Days Payable is 67.97. Positron's value of 58.33 is 14.2% below this industry median. Based on the distribution chart, Positron ranks #478 out of 794 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Positron has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Positron's Days Payable compare to MDAI and ECOR?
According to the Medical Devices & Instruments industry distribution chart, Positron ranks #478 out of 794 companies for Days Payable. This places Positron in the lower half of its industry. The industry median Days Payable is 67.97. Positron's value of 58.33 is 14.2% below this benchmark. Historically, Positron's own Days Payable has ranged from 50.27 to 511.94 over the past decade. While the company's 10-year median is 213.73 vs. the industry median of 67.97, Positron has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Positron's current Days Payable of 58.33 is 14.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Positron and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Positron's current Days Payable is 58.33, which is 73% below median its own 10-year median of 213.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Positron stock overvalued right now?
Based on GuruFocus' analysis, Positron (POSC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.12, compared to a current price of $1.76 — trading 1368.3% above its estimated fair value. The current Days Payable is 58.33, which is 73% below median its 10-year median of 213.73 and 14.2% below the Medical Devices & Instruments industry median of 67.97. Positron's overall GF Score™ is 30/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Positron (POSC), the current Days Payable is 58.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Positron (POSC) Overvalued in 2026?
Based on GuruFocus' analysis, Positron stock appears to be overvalued.
The current stock price of $1.76 is trading 1368.3% above its estimated GF Value™ of $0.12.
GuruFocus considers Positron to be Significantly Overvalued.
Key valuation signals for POSC:
Days Payable: 58.33 (73% below median its 10-year median of 213.73)
GF Value™: $0.12 vs. price of $1.76 (1368.3% above fair value)
Industry Position: 14.2% below the Medical Devices & Instruments median (#478 of 794)
No single metric tells the full story. See the POSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Positron Corp is a medical technology company engaged in the co-development, manufacture, and sale of PET and PET-CT imaging systems, delivering high-performance, cost-effective molecular imaging solutions that empower healthcare providers to improve the diagnosis and treatment of cardiovascular disease and other critical conditions. By combining proprietary PET and PET-CT systems with comprehensive clinical and technical support, flexible financing, & a focus on operational efficiency, Positron makes advance diagnostic imaging more accessible & sustainable for hospitals, outpatient centers, & physician practices. The company focused on advancing positron emission tomography imaging through the development, manufacture, & commercialization of PET & PET-computed tomography imaging systems.
30GF Score
Get the complete analysis for POSC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POSC has been successfully added to your 
